⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1192698 | 0.74 | — | — | |
| SCHEMBL1378944 | 0.74 | — | — | |
| SCHEMBL2569647 | 0.73 | — | — | |
| SCHEMBL10828133 | 0.71 | TSHR (0.39) | — | |
| SCHEMBL2568029 | 0.71 | — | — | |
| SCHEMBL13889070 | 0.71 | — | — | |
| SCHEMBL18868463 | 0.71 | — | — | |
| SCHEMBL13765939 | 0.71 | — | — | |
| SCHEMBL13673837 | 0.71 | — | — | |
| SCHEMBL789547 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106661355-B | Ink composition, inkjet recording method, and colored body | 日本化药株式会社 | 2020-06-12 | — | — | CN | disclosed |
| US-10544320-B2 | Ink composition, inkjet recording method, and colored article | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2020-01-28 | — | — | US | disclosed |
| EP-3153555-B1 | INK COMPOSITION, INKJET RECORDING METHOD, AND COLORED ARTICLE | NIPPON KAYAKU KK (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20170137652-A1 | INK COMPOSITION, INKJET RECORDING METHOD, AND COLORED ARTICLE | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2017-05-18 | — | — | US | disclosed |
| EP-3153555-A1 | INK COMPOSITION, INKJET RECORDING METHOD, AND PRINT ARTICLE | Nippon Kayaku Kabushiki Kaisha (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-20120225062-A1 | NOVEL KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| EP-2382972-A1 | Methods for preventing and treating neurodegenerative disorders | Boehringer Ingelheim International GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| EP-2124965-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008090210-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | WO | disclosed |
| US-6710060-B2 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20020188006-A1 | 4-hydroxypiperidine derivatives having antiarrhythmic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-12 | — | — | US | disclosed |
| EP-1182192-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |